Patent cliffs don’t just reshape pipelines—they reshape budgets.
For procurement leaders and supply chain teams, the “patent cliff” moment is often treated like a downstream event: a forecast, a contract renegotiation, a scramble for alternative supp…

Generic drug companies are facing a quiet squeeze—and it’s not just about pricing. It’s about survival math.
For years, the generic model was straightforward: win approvals, scale manufacturing, compete on cost, and let volume do the heavy lifting. But…

Branded pharma’s revenue model is under siege—and the threats aren’t subtle.
In a recent piece, DrugPatentWatch lays out eight “brutal problems” that are quietly (and sometimes loudly) eroding the economics of branded drug companies. The headline takea…

Generic drug competition isn’t won in the lab—it’s won in the filing. And nowhere is that more obvious than in the FDA’s Orange Book, where the “time and win” playbook for market entry is quietly written.
If you’ve ever wondered how generic manufacture…

Biopharma is hiring for “IP,” but too many teams still treat IP like a silo—something you hand to legal after the strategy is set.
The result? Valuable knowledge gets trapped in decks, job descriptions stay vague, and portfolios don’t translate into or…

The Generic Cliff Isn’t a Cliff—It’s a Deadline. Here’s How Pharma Engineers Around It.
If you’ve ever watched a blockbuster drug’s patent clock run down, you know the story: once exclusivity expires, generics rush in, prices fall, and revenue curves b…

Drug companies don’t just “get patents.” They build ecosystems.
That’s the uncomfortable truth behind how patent thickets form around biologic blockbusters—and why the fight over access, pricing, and innovation is increasingly a fight over patent str…

Russia’s latest VED/SSM list update is a reminder that “generic timing” isn’t just a legal exercise—it’s an intelligence game.
If you’re a brand team, you’re watching for signals that competitors are lining up their launch calendars. If you’re a generi…